Engineered immune cells take on tough lymphomas
NCT ID NCT04792489
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to recognize and attack cancer cells. The study aims to see if this approach can shrink tumors and control the disease in people with several types of lymphoma, including diffuse large B cell lymphoma and mantle cell lymphoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zamtocabtagene autoleucel (MB-CART2019.1) with chemotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat B cell lymphomas, potentially leading to long-term disease control.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone. There are risks of serious side effects, including cytokine release syndrome and nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network Cancer Institute
RECRUITINGPittsburgh, Pennsylvania, 15212, United States
Contact Email: •••••@•••••
-
Banner MD Anderson Cancer Center
RECRUITINGGilbert, Arizona, 85234, United States
Contact Email: •••••@•••••
-
Baptist Health Miami Cancer Institute
RECRUITINGMiami, Florida, 33176, United States
Contact Email: •••••@•••••
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact Email: •••••@•••••
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Duke University Medical Center - Division of Hematologic Malignancies
RECRUITINGDurham, North Carolina, 27705, United States
Contact Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
-
Froedtert Hospital and the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
-
Georgia Cancer Center at Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
Contact Email: •••••@•••••
-
Mayo Clinic
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
Oregon Health and Science University Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Email: •••••@•••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, ON M5G 2C4, Canada
Contact Email: •••••@•••••
-
Robert H Lurie Cancer Center
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
-
Texas Transplant Institute
RECRUITINGSan Antonio, Texas, 98109, United States
Contact Email: •••••@•••••
-
The Ohio State University Wexner Medical Center James Cancer
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
UC San Diego Health
RECRUITINGLa Jolla, California, 92037, United States
Contact Email: •••••@•••••
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Email: •••••@•••••
-
University of Alberta Cross Cancer Institute
RECRUITINGEdmonton, Alberta, AB T6G 1Z2, Canada
Contact Email: •••••@•••••
-
University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Email: •••••@•••••
-
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
-
University of Nebraska Medical Center
TERMINATEDOmaha, Nebraska, 68198, United States
-
University of Pittsburgh - Hillman Cancer Center
WITHDRAWNPittsburgh, Pennsylvania, 15260, United States
-
Washington University, St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chemo-free cocktail tame mantle cell lymphoma?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- New drug duo aims to outsmart resistant lymphoma
- Can a Macrophage-Targeting drug supercharge CAR-T therapy?
- New cocktail aims to tame aggressive lymphoma in the very elderly
- Promising drug may shrink brain tumors in relapsed lymphoma